Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Primarily, this clinical investigation compares the rates (percentages) of pathological
complete remissions attained at the time of final surgery following 6 cycles each of
epirubicin + docetaxel + capecitabine-containing chemotherapy ± trastuzumab (in HER-2
positive disease) vs. epirubicin + docetaxel-containing chemotherapy ± trastuzumab (in HER-2
negative disease).